Couverture de Just BOLD Enough

Just BOLD Enough

Just BOLD Enough

De : Teymour Boutros-Ghali and Felicia Hsu
Écouter gratuitement

À propos de ce contenu audio

Welcome to Just BOLD Enough, where we explore BOLD Capital Partner’s mission to invest in healthcare and technology companies that disrupt industries and uplift humanity. We’ll share expert insights and have engaging discussions on impact, investment philosophy, and our perspective on the very issues shaping our world. Get ready to embrace innovation with purpose – this is Just BOLD Enough.

To learn more, visit:
https://boldcapitalpartners.com/

© 2024 Mission Matters Podcast Agency
Hygiène et vie saine Politique et gouvernement Science
Les membres Amazon Prime bénéficient automatiquement de 2 livres audio offerts chez Audible.

Vous êtes membre Amazon Prime ?

Bénéficiez automatiquement de 2 livres audio offerts.
Bonne écoute !
    Épisodes
    • Figure AI
      Jun 6 2024

      The conversation explores the topic of humanoid robots and how science fiction is becoming a reality. The principal themes include the advancements in language and visual models, the reduction in mechanical costs, the importance of humanoid shape, the near-term markets for humanoid robots, and the companies involved in this field.

      Story Notes:

      • Advancements in Language and Visual Models
      • The Importance of Humanoid Shape
      • Near-Term Markets for Humanoid Robots
      • Figure AI: Leading the Way in Humanoid Robotics

      To learn more, visit:
      https://boldcapitalpartners.com/

      Afficher plus Afficher moins
      15 min
    • Syntis Bio: Solutions to Unlock Obesity and Metabolic Disorders
      Apr 25 2024

      In this episode of Just Bold Enough, Teymour and Felicia discuss an innovative biotech company, Syntis Bio, and how it will disrupt obesity treatment. Syntis has developed a gastric bypass-in-a-pill that blocks the absorption of glucose in the small intestine. This simple, yet clever solution could revolutionize the treatment of obesity and have a significant impact on the pharmaceutical industry by improving the delivery of other drugs. The team is led by experienced CEO, Rahul Dhanda, who is now leading the company into human clinical trials. The company also prioritizes health equity by aiming to disrupt the high cost of obesity treatments such as Ozempic and make it more accessible to those who need it.

      Story Notes:

      • Addressing the Obesity Challenge
      • Navigating the Regulatory Landscape
      • The Potential Impact on the Pharmaceutical Industry

      To learn more, visit:
      https://boldcapitalpartners.com/

      Afficher plus Afficher moins
      27 min
    • Insilico Medicine: A Leader in AI-driven Pharma Innovation
      Apr 11 2024

      Insilico Medicine uses generative AI for drug discovery and has set the trend for AI in the pharmaceutical industry. They have developed an AI platform to identify novel targets and molecules, significantly reducing the time and cost of the drug discovery process. The company has a pipeline of novel molecules and drugs, with one asset in clinical trials for idiopathic pulmonary fibrosis (IPF). They’ve gained the trust of the pharma industry and have partnerships with big pharma and contract research organizations.

      Story Notes:

      • Introduction and Background of Insilico Medicine
      • Understanding Generative AI
      • Insilico Medicine's Approach to Drug Discovery
      • The Visionary Leadership of Alex Zhavoronkov


      To learn more, visit:
      https://boldcapitalpartners.com/

      Afficher plus Afficher moins
      30 min
    Aucun commentaire pour le moment